Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 511 - 520 of 785 studies

Oral and Gastrointestinal

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

Cancer and neoplasms

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

A pilot study: Sequential sampling of Blood and MRI based biomarkers of thrombogenesis following termination of Atrial Fibrillation episodes.

Investigating human biology of resident immunity in tissue via neoantigen challenge

Metabolic and Endocrine

A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01Positive Participants With Type 1 Diabetes (IMC-S118AI-1007)

Musculoskeletal

A Phase 3, Multi centre, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

Neurological

NIO752 A randomized, placebo-controlled, parallel group, 72-week study to evaluate the efficacy of NIO752 in participants with Progressive Supranuclear palsy followed by an Open Label Extension (CNIO752A12301 (PRESERVE))

Comparative evaluation of sustained meChanical AsPiration Thrombectomy and no thrombus modification for pre-stent thrombus bUrden Reduction in patients with Acute Myocardial Infarction Study: the CAPTURE AMI Study

Cancer and neoplasms

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Fluoropyrimidine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02) (D9803C00001 (CLARITY-Gastric 02))

CAPTIVATE - Diet-driven gut microbiome and outcome in patients with early-stage triple-negative breast cancer undergoing neoadjuvant chemotherapy and immunotherapy